Involvement of kynurenines in Huntington's disease and stroke-induced brain damage

Journal of Neural Transmission

Volumn 119, Issue 2, 2012, Pages 261-274

  Stone, Trevor W ^a   Forrest, Caroline M ^a   Stoy, Nicholas ^b   Darlington, L Gail ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROYAL HOSPITAL FOR NEURO DISABILITY   (United Kingdom)

^c Ashtead Hospital   (United Kingdom)

Author keywords

Cognition; Huntington's disease; Kynurenic acid; Kynurenine; Neurodegeneration; Quinolinic acid; Stroke; Tryptophan

Indexed keywords

GLUTAMIC ACID; HUNTINGTIN; KYNURENINE; NICOTINIC RECEPTOR; REACTIVE OXYGEN METABOLITE; TRYPTOPHAN;

AGE; BRAIN DAMAGE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; CORRELATION ANALYSIS; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; INJURY; MORTALITY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; STROKE; TRYPTOPHAN METABOLISM;

ANIMALS; BRAIN; HUMANS; HUNTINGTON DISEASE; KYNURENINE; STROKE;

EID: 84857633327     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0676-8     Document Type: Review

References (140)

1. A Amann B Widner J Rieder H Antretter G Hoffmann V Mayr HU Strohmenger D Fuchs 2001 Monitoring of immune activation using biochemical changes in a porcine model of cardiac arrest Mediat Inflamm 10 343 346 1:CAS:528: DC%2BD38XhvFGgsrg%3D 10.1080/09629350120102370 (Pubitemid 34084415)
2. L Bacciottini DE Pellegrini-Giampietro F Bongianno G Deluca M Beni V Politi F Moroni 1987 Biochemical and behavioral-studies on indole-pyruvic acid-a keto-analogue of tryptophan Pharmacol Res Commun 19 803 817 2451257 1:CAS:528:DyaL1cXhtVKgsb0%3D 10.1016/0031-6989(87)90014-2 (Pubitemid 18030717)
3. H Baran B Kepplinger M Herrera-Marschitz K Stolze G Lubec H Nohl 2001 Increased kynurenic acid in the brain after neonatal asphyxia Life Sci 69 1249 1256 11521749 1:CAS:528:DC%2BD3MXlvVSktL4%3D 10.1016/S0024-3205(01)01215-2 (Pubitemid 32758695)
4. FC Barone KS Kilgore 2006 Role of inflammation and cellular stress in brain injury and central nervous system diseases Clin Neurosci Res 6 329 356 1:CAS:528:DC%2BD28Xht12ksb3F 10.1016/j.cnr.2006.09.010 (Pubitemid 44849180)
5. G Bates 2003 Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 1642 1644 12747895 1:CAS:528:DC%2BD3sXjs1Wluro%3D 10.1016/S0140-6736(03)13304-1 (Pubitemid 36579005)
6. TM Bauer LP Jiga JJ Chuang M Randazzo G Opelz P Terness 2005 Studying the immunosuppressive role of indoleamine 2, 3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo Transpl Intern 18 95 100 1:CAS:528:DC%2BD2MXksFCgtLk%3D 10.1111/j.1432-2277.2004.00031.x (Pubitemid 41742952)
7. MF Beal WR Matson E Storey P Milbury EA Ryan T Ogawa ED Bird 1992 Kynurenic acid concentrations are reduced in Huntington's disease J Neurol Sci 108 80 87 1385624 1:CAS:528:DyaK38XisFensL8%3D 10.1016/0022-510X(92)90191-M
8. MF Beal NW Kowall DW Ellison MF Mazurek KJ Swartz JB Martin 1986 Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid Nature 321 168 171 2422561 1:CAS:528:DyaL28XktVCmtrg%3D 10.1038/321168a0 (Pubitemid 16022019)
9. MF Beal KJ Swartz SF Finn MF Mazurek NW Kowall 1991 Neurochemical characterization of excitotoxin lesions in the cerebral cortex J Neurosci 11 147 158 1670782 1:CAS:528:DyaK3MXhvVehu7w%3D
10. MF Beal RJ Ferrante KJ Swartz NW Kowall 1991 Chronic quinolinic acid lesions in rats closely resemble Huntington's disease J Neurosci 11 1649 1659 1710657 1:CAS:528:DyaK3MXlsFKgtLo%3D
11. WMH Behan TW Stone 2000 Role of kynurenines in the neurotoxic actions of kainic acid Br J Pharmacol 129 1764 1770 10780984 1:CAS:528:DC%2BD3cXjtV2qsrs%3D 10.1038/sj.bjp.0703250 (Pubitemid 30219021)
12. M Bjorkqvist EJ Wild J Thiele A Silvestroni R Andre N Lahiri, et al. 2008 A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J Exp Med 205 1869 1877 18625748 10.1084/jem.20080178 1:CAS:528:DC%2BD1cXpsFOjsLg%3D
13. ML Block L Zecca JS Hong 2007 Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat Rev Neurosci 8 57 69 17180163 1:CAS:528:DC%2BD28XhtlemtL7M 10.1038/nrn2038 (Pubitemid 46011999)
14. ML Block JS Hong 2005 Microglia and inflammation-mediated neurodegenration: multiple triggers with a common mechanism Prog Neurobiol 76 77 98 16081203 1:CAS:528:DC%2BD2MXpvFemu7o%3D 10.1016/j.pneurobio.2005.06.004 (Pubitemid 41242883)
15. R Brouns R Verkerk T Aerts D De Surgeloose A Wauters S Scharpe PP De Deyn 2010 The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke Neurochem Res 35 1315 1322 20490917 1:CAS:528: DC%2BC3cXmtlamtLs%3D 10.1007/s11064-010-0187-2
16. SE Browne RJ Ferrante MF Beal 1999 Oxidative stress in Huntington's disease Brain Pathol 9 147 163 9989457 1:CAS:528:DyaK1MXht1Cmsb0%3D 10.1111/j.1750-3639.1999.tb00216.x (Pubitemid 29056525)
17. LH Burns P Pakzaban TW Deacon AL Brownell SB Tatter BG Jenkins O Isacson 1995 Selective putaminal excitotoxic lesions in nonhuman-primates model the movement disorder of Huntington disease Neuroscience 64 1007 1017 7753372 1:CAS:528:DyaK2MXjvVGksL0%3D 10.1016/0306-4522(94)00431-4
18. R Carpenedo A Chiarugi P Russi G Lombardi V Carla R Pellicciari F Moroni L Mattoli 1994 Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities Neuroscience 61 237 244 7969905 1:CAS:528:DyaK2cXmsVGru7g%3D 10.1016/0306-4522(94)90227-5 (Pubitemid 24219003)
19. RJ Carter LA Lione T Humby L Mangiarini A Mahal GP Bates, et al. 1999 Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation J Neurosci 19 3248 3257 10191337 1:CAS:528:DyaK1MXitlGmsro%3D (Pubitemid 29174016)
20. CJ Clark GM Mackay GA Smythe S Bustamante TW Stone RS Phillips 2005 Prolonged survival of a murine model of cerebral malaria by kynurenine pathway inhibition Infect Immun 73 5249 5251 16041050 1:CAS:528:DC%2BD2MXmvVCit70%3D 10.1128/IAI.73.8.5249-5251.2005 (Pubitemid 41105691)
21. JH Connick GC Heywood GJ Sills GG Thompson MJ Brodie TW Stone 1992 Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity Gen Pharmacol 23 235 239 1639238 1:CAS:528: DyaK38Xit1yjtL8%3D 10.1016/0306-3623(92)90017-E
22. CM Cowan MMY Fan J Fan J Shehadeh LYJ Zhang RK Graham, et al. 2008 Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity J Neurosci 28 12725 12735 19036965 1:CAS:528:DC%2BD1cXhsVKgsbrE 10.1523/JNEUROSCI.4619-08. 2008
23. R Cozzi R Carpenedo F Moroni 1999 Kynurenine hydroxylase inhibitors reduce ischaemic brain damage: studies with (m-nitrobenzoyl)alanine and 3, 4-dimethoxy-[N-4-(nitrophenyl)thiazol-2-yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global ischaemia J Cereb Blood Flow Metab 19 771 777 10413032 1:CAS:528:DC%2BD3cXksVCqsbk%3D 10.1097/00004647-199907000-00007 (Pubitemid 30159803)
24. LG Darlington GM Mackay CM Forrest N Stoy C George TW Stone 2007 Altered kynurenine metabolism correlates with infarct volume in stroke Eur J Neurosci 26 2211 2221 17892481 1:STN:280:DC%2BD2snisVersQ%3D%3D 10.1111/j.1460-9568.2007. 05838.x (Pubitemid 47620487)
25. Darlington LG, Forrest CM, Mackay GM, Stoy N, Smith RA, Smith AJ, Stone TW (2010) On the biological significance of the 3-hydroxyanthranilic acid:anthranilic acid ratio. Int J Tryptophan Res 3:51-59
26. JA Dykens SG Sullivan A Stern 1987 Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, quinolinate and picolinate Biochem Pharmacol 36 211 217 2949752 1:CAS:528:DyaL2sXhtlems7o%3D 10.1016/0006-2952(87)90691-5 (Pubitemid 17004917)
27. CL Eastman TR Guilarte 1989 Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line Brain Res 495 225 231 2765927 1:CAS:528: DyaL1MXlsVygtb4%3D 10.1016/0006-8993(89)90216-3 (Pubitemid 19213559)
28. CL Eastman TR Guilarte 1990 The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine Neurochem Res 15 1101 1107 2089269 1:CAS:528:DyaK3MXps1Cqtw%3D%3D 10.1007/BF01101711
29. MG Espey ON Chernyshev JF Reinhard MAA Namboodiri CA Colton 1997 Activated human microglia produce the excitotoxin quinolinic acid Neuroreport 8 431 434 9080423 1:CAS:528:DyaK2sXisVaisrY%3D 10.1097/00001756-199701200-00011 (Pubitemid 27180096)
30. MG Espey JR Moffett MAA Namboodiri 1995 Temporal and spatial changes of quinolinic acid immunoreactivity in the immune-system of lipopolysaccharide- stimulated mice J Leukocyte Biol 57 199 206 7852833 1:CAS:528:DyaK2MXjsFOhtrs%3D
31. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Paolino E, Tola MR, Granieri E, Baricordi OR (2006) Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler 12:2-12 (Pubitemid 43169232)
32. U Feger E Tolosa Y-H Huang A Waschbisch T Biedermann A Melms H Wiendl 2007 HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation Blood 110 568 577 17371944 1:CAS:528:DC%2BD2sXot1emtrw%3D 10.1182/blood-2006-11-057125 (Pubitemid 47105395)
33. CM Forrest GM Mackay N Stoy M Egerton J Christofides TW Stone LG Darlington 2004 Tryptophan loading induces oxidative stress Free Radic Res 38 1167 1171 15621693 1:CAS:528:DC%2BD2cXhtFSntr7L 10.1080/10715760400011437 (Pubitemid 39654505)
34. CM Forrest GM Mackay N Stoy SL Spiden R Taylor TW Stone LG Darlington 2010 Blood levels of kynurenines, interleukin IL-23 and sHLA-G at different stages of Huntington's disease J Neurochem 112 112 122 19845828 1:CAS:528:DC%2BC3cXhs1GhsQ%3D%3D 10.1111/j.1471-4159.2009.06442.x
35. CM Forrest GM Mackay L Oxford N Stoy TW Stone LG Darlington 2006 Kynurenine pathway metabolism in patients with osteoporosis after two years of drug treatment Clin Exp Pharmacol Physiol 33 1078 1087 17042918 1:CAS:528:DC%2BD28Xht1akt7zP 10.1111/j.1440-1681.2006.04490.x (Pubitemid 44581571)
36. D Fuchs A-A Moeller G Reibnegger E Stoeckle E-R Werner H Wachter 1990 Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms J Acquir Immune Defic Syndr 3 873 876 2166783 1:CAS:528:DyaK3MXpvFOmtA%3D%3D (Pubitemid 20330669)
37. J Gayán D Brocklebank JM Andresen G Alkorta-Aranburu US-Venezuela Collaborative Research Group M Zameel Cader SA Roberts SS Cherny NS Wexler LR Cardon DE Housman 2008 Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds Genet Epidemiol 32 445 453 18481795 10.1002/gepi.20317
38. J Gehrmann RB Banati C Wiessnert KA Hossmann GW Kreutzberg 1995 Reactive microglia in cerebral ischemia-an early mediator of tissue damage Neuropathol Appl Neurobiol 21 277 289 7494596 1:STN:280:DyaK28%2Fls1KjtA%3D%3D 10.1111/j.1365-2990.1995.tb01062.x
39. GI Giles CA Collins TW Stone C Jacob 2003 Electrochemical and in vitro evaluation of the redox properties of kynurenine species Biochem Biophys Res Commun 300 719 724 12507509 1:CAS:528:DC%2BD38XpvVWlsrY%3D 10.1016/S0006- 291X(02)02917-0 (Pubitemid 36268896)
40. F Giorgini P Guidetti QV Nguyen SC Bennett PJ Muchowski 2005 A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease Nat Genet 37 526 531 15806102 1:CAS:528: DC%2BD2MXjsF2ksrs%3D 10.1038/ng1542 (Pubitemid 40617282)
41. F Giorgini T Moller W Kwan D Zwilling JL Wacker S Hong LC-L Tsai CS Cheah R Schwarcz P Guidetti PJ Muchowski 2008 Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia and mice expressing a mutant huntingtin fragment J Biol Chem 283 7390 7400 18079112 1:CAS:528:DC%2BD1cXjt1emtbc%3D 10.1074/jbc.M708192200
42. LE Goldstein MC Leopold X Huang, et al. 2000 3-Hydroxykynurenine and 3-hydroxy-anthranilic acid generate hydrogen peroxide and promote α-crystallin cross-linking by metal ion reduction Biochemistry 39 7266 7275 10852726 1:CAS:528:DC%2BD3cXjsFSntbY%3D 10.1021/bi992997s (Pubitemid 30413117)
43. A Gonzalez-Hernandez J LeMaoult A Lopez E Alegre J Caumartin S Le Rond, et al. 2005 Linking two immuno-suppressive molecules: indoleamine 2, 3 dioxygenase can modify HLA-G cell-surface expression Biol Reprod 73 571 578 15878889 1:CAS:528:DC%2BD2MXovV2qtLY%3D 10.1095/biolreprod.105.040089 (Pubitemid 41170213)
44. P Guidetti R Schwarcz 1999 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum Eur J Neurosci 11 3857 3863 10583474 1:STN:280:DC%2BD3c%2FltFajtQ%3D%3D 10.1046/j.1460-9568.1999.00806.x (Pubitemid 29537565)
45. P Guidetti PH Reddy DA Tagle R Schwarcz 2000 Early kynureninergic impairment in Huntington's disease and in a transgenic animal model Neurosci Lett 283 233 235 10754231 1:CAS:528:DC%2BD3cXit1Wgtbg%3D 10.1016/S0304-3940(00) 00956-3 (Pubitemid 30168976)
46. P Guidetti RE Luthi-Carter SJ Augood R Schwarcz 2004 Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease Neurobiol Dis 17 455 461 15571981 1:CAS:528:DC%2BD2cXhtVansbjP 10.1016/j.nbd.2004.07.006 (Pubitemid 39574879)
47. P Guidetti GP Bates RK Graham MR Hayden BR Leavitt ME MacDonald EJ Slow VC Wheeler B Woodman R Schwarcz 2006 Elevated brain 3-hydroxykynurenine and quinolinate in Huntington disease mice Neurobiol Dis 23 190 197 16697652 1:CAS:528:DC%2BD28XlvFyqtrY%3D 10.1016/j.nbd.2006.02.011 (Pubitemid 43922462)
48. GJ Guillemin KM Cullen CK Lim GA Smythe B Garner V Kapoor O Takikawa BJ Brew 2007 Characterization of the kynurenine pathway in human neurons J Neurosci 27 12884 12892 18032661 1:CAS:528:DC%2BD2sXhsVWrsr3F 10.1523/JNEUROSCI.4101-07. 2007 (Pubitemid 350161746)
49. C Haass DJ Selkoe 2007 Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat Rev Mol Cell Biol 8 101 112 17245412 1:CAS:528:DC%2BD2sXotFKmtw%3D%3D 10.1038/nrm2101 (Pubitemid 46432529)
50. CA Harris AF Miranda JJ Tanguay RJ Boegman RJ Beninger K Jhamandas 1998 Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid Br J Pharmacol 124 391 399 9641558 1:CAS:528: DyaK1cXjs1Ogurs%3D 10.1038/sj.bjp.0701834 (Pubitemid 28248031)
51. B Hassel S Tessler RLM Faull PC Emson 2008 Glutamate uptake is reduced in prefrontal cortex in Huntington's disease Neurochem Res 33 232 237 17726644 1:CAS:528:DC%2BD1cXps1WntA%3D%3D 10.1007/s11064-007-9463-1
52. MY Heng PJ Detloff PL Wang JZ Tsien RL Albin 2009 In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease J Neurosci 29 3200 3205 19279257 1:CAS:528:DC%2BD1MXjsVamt7s%3D 10.1523/JNEUROSCI.5599-08.2009
53. MP Heyes 1993 Quinolinic acid and inflammation Ann NY Acad Sci 679 211 216 8512184 1:CAS:528:DyaK3sXks12itLk%3D 10.1111/j.1749-6632.1993.tb18300.x (Pubitemid 23202410)
54. MP Heyes K Saito JS Crowley LE Davis MA Demitrack M Der LA Dilling J Elia MJP Kruesi A Lackner SA Larsen K Lee HL Leonard SP Markey A Martin S Milstein MM Mouradian MR Pranzatelli BJ Quearry A Salazar M Smith SE Strauss T Sunderland SW Swedo WW Tourtellotte 1992 Quinolinic acid and kynurenine pathway metabolism in inflammatory and noninflammatory neurological disease Brain 115 1249 1273 1422788 10.1093/brain/115.5.1249
55. MP Heyes K Saito SP Markey 1992 Human macrophages convert l-tryptophan into the neurotoxin quinolinic acid Biochem J 283 633 635 1534219 1:CAS:528:DyaK38XktVGru7w%3D
56. MP Heyes CL Achim CA Wiley EO Major K Saito SP Markey 1996 Human microglia convert l-tryptophan into the neurotoxin quinolinic acid Biochem J 320 595 597 8973572 1:CAS:528:DyaK2sXivVGh (Pubitemid 26417785)
57. C Hilmas EF Pereira M Alkondon A Rassoulpour R Schwarcz 2001 The brain metabolites kynurenic acid inhibits α7-nicotinic receptor activity and increases non-α7 nicotinic receptor expression J Neurosci 21 7463 7473 11567036 1:CAS:528:DC%2BD3MXnsFCksrc%3D (Pubitemid 32904945)
58. G Hoffmann W Schobersberger 2004 Neopterin: a mediator of the cellular immune system Pteridines 15 107 112 1:CAS:528:DC%2BD2cXotFaqt70%3D (Pubitemid 39280261)
59. Q Huang D Zhou E Sapp H Aizawa P Ge ED Bird, et al. 1995 Quinolinic acid-induced increases in calbindin-d-28 k immunoreactivity in rat striatal neurons in-vivo and in-vitro mimic the pattern seen in Huntingtons-disease Neuroscience 65 397 407 7777157 1:CAS:528:DyaK2MXkt1ymtL8%3D 10.1016/0306-4522(94)00494-P
60. J Huang UM Uphadyay RJ Tamargo 2006 Inflammation in stroke and focal cerebral ischemia Surg Neurol 66 232 245 16935624 10.1016/j.surneu.2005.12.028 (Pubitemid 44279808)
61. PE Hughes T Alexi CE Williams RG Clark PD Gluckman 1999 Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease Neuroscience 92 197 209 10392842 1:CAS:528:DyaK1MXjs1ymsr4%3D 10.1016/S0306-4522(98)00724-6 (Pubitemid 29249030)
62. JS Hunt DL Langat 2009 HLA-G: a human pregnancy modulator Curr Opin Pharmacol 9 462 469 19570712 1:CAS:528:DC%2BD1MXhtVenurbE 10.1016/j.coph.2009. 05.007
63. D Jauch EM Urbanska P Guidetti ED Bird JP Vonsattel WO Whetsell R Schwarcz 1995 Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferase J Neurol Sci 130 39 47 7650530 1:STN:280:DyaK2MznvVynuw%3D%3D 10.1016/0022-510X(94)00280-2
64. T Kanai T Fujii S Kozuma T Yamashita A Miki A Kikuchi Y Taketani 2001 Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture Mol Human Reprod 7 195 200 1:CAS:528:DC%2BD3MXhsFahtro%3D 10.1093/molehr/7.2.195 (Pubitemid 32148347)
65. B Kepplinger H Baran A Kainz H Ferraz-Leite J Newcombe P Kalina 2005 Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and beta(2)-microglobulin changes Neurosignals 14 126 135 16088227 1:CAS:528:DC%2BD2MXntFSnt7g%3D 10.1159/000086295 (Pubitemid 41160299)
66. S Kuemmerle CA Gutekunst AM Klein XJ Li SH Li MF Beal SM Hersch, et al. 1999 Huntingtin aggregates may not predict neuronal death in Huntington's disease Ann Neurol 46 842 849 10589536 1:STN:280:DC%2BD3c%2FlsFCmsQ%3D%3D 10.1002/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O
67. S Le Rond A Gonzalez ASL Gonzalez ED Carosella N Rouas-Freiss 2005 Indoleamine 2, 3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways Immunology 116 297 307 16236119 1:CAS:528:DC%2BD2MXht1Sitb3N 10.1111/j.1365-2567.2005.02224.x (Pubitemid 41532122)
68. F Leblhuber J Walli K Jellinger GP Tilz B Widner F Laccone D Fuchs 1998 Activated immune system in patients with Huntington's disease Clin Chem Lab Med 36 747 750 9853799 1:CAS:528:DyaK1cXnsFagtrg%3D 10.1515/CCLM.1998.132 (Pubitemid 28521525)
69. SM Lee YS Lee JH Choi SG Park IW Choi YD Joo WS Lee JN Lee I Choi K Seo 2010 Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion Immunol Lett 132 53 60 20570696 1:CAS:528:DC%2BC3cXptVamsb4%3D 10.1016/j.imlet.2010.05.008
70. G Leipnitz C Schumacher KB Dalcin, et al. 2006 In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain Neurochem Int 50 83 94 16959377 10.1016/j.neuint.2006.04.017 1:CAS:528:DC%2BD28Xht12msrfL
71. AS López E Alegre J LeMaoult E Carosella A González 2006 Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells Mol Immunol 43 2151 2160 16490253 10.1016/j.molimm.2006.01.007 1:CAS:528:DC%2BD28XlsFCns7s%3D (Pubitemid 43831200)
72. AS López E Alegre A Díaz-Lagares C García- Girón MJ Coma A González 2008 Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages Immunol Lett 117 91 95 18289708 10.1016/j.imlet.2008.01.001 1:CAS:528:DC%2BD1cXjtlWgtrs%3D
73. GM Mackay CM Forrest N Stoy J Christofides M Egerton TW Stone LG Darlington 2006 Tryptophan metabolism and oxidative stress in patients with chronic brain injury Eur J Neurol 13 30 42 16420391 1:STN:280: DC%2BD28%2FjtlSjsQ%3D%3D 10.1111/j.1468-1331.2006.01220.x
74. L Marquardt A Ruf U Mansmann R Winter F Buggle K Kallenberg AJ Grau 2005 Inflammatory response after acute stroke J Neurol Sci 236 65 71 15961109 1:CAS:528:DC%2BD2MXpsVWktrs%3D 10.1016/j.jns.2005.05.006 (Pubitemid 41218694)
75. G Matteoli E Mazzini ID Iliev E Mileti F Fallarino P Puccetti M Chieppa M Rescigno 2010 Gut CD103+dendritic cells express indoleamine 2, 3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction Gut 59 595 604 20427394 1:CAS:528:DC%2BC3cXnvFKiu7Y%3D 10.1136/gut.2009.185108
76. JD Mezrich JH Fechner X Zhang BP Johnson WJ Burlingham CA Bradfield 2010 An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells J Immunol 185 3190 3198 20720200 1:CAS:528: DC%2BC3cXhtFSntL7F 10.4049/jimmunol.0903670
77. BR Miller JL Dorner M Shou Y Sari SJ Barton DR Sengelaub, et al. 2008 Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse Neuroscience 153 329 337 18353560 1:CAS:528:DC%2BD1cXkvVOkurg%3D 10.1016/j.neuroscience.2008.02.004
78. F Moroni 1999 Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites Eur J Pharmacol 375 87 100 10443567 1:CAS:528:DyaK1MXks1Crsro%3D 10.1016/S0014-2999(99)00196-X (Pubitemid 29317595)
79. DH Munn M Zhou JT Attwood I Bondarev SJ Conway B Marshall, et al. 1998 Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 1191 1193 9712583 1:CAS:528:DyaK1cXls1Cqu7c%3D 10.1126/science.281.5380.1191 (Pubitemid 28406294)
80. Y Nakagami H Saito H Katsuki 1996 3-Hydroxykynurenine toxicity on the rat striatum in vivo Jpn J Pharmacol 71 183 186 8835646 1:CAS:528: DyaK28XjvVWku7g%3D 10.1254/jjp.71.183 (Pubitemid 26235604)
81. K Narui N Noguchi A Saito K Kakimi N Motomura K Kubo 2009 Anti-infectious activity of tryptophan metabolites in the l-tryptophan-l-kynurenine pathway Biol Pharm Bull 32 41 44 19122278 1:CAS:528:DC%2BD1MXmsVGmurw%3D 10.1248/bpb.32.41
82. H Nemeth J Toldi L Vecsei 2005 Role of kynurenines in the central and peripheral nervous systems Curr Neurovasc Res 2 249 260 16181118 10.2174/1567202054368326 (Pubitemid 40980183)
83. S Okuda N Nishiyama H Saito H Katsuki 1996 Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine Proc Natl Acad Sci USA 93 12553 12558 8901620 1:CAS:528:DyaK28Xms1Ghuro%3D 10.1073/pnas.93.22.12553 (Pubitemid 26367182)
84. S Okuda N Nishiyama H Saito H Katsuki 1998 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity J Neurochem 70 299 307 9422375 1:CAS:528:DyaK1cXmt1Wk 10.1046/j.1471-4159.1998.70010299.x (Pubitemid 28020856)
85. SJ Pearson GP Reynolds 1992 Increased brain concentrations of a neurotoxin, 3-hydroxy-kynurenine, in Huntington's disease Neurosci Lett 144 199 201 1436703 1:CAS:528:DyaK3sXpvFGnsw%3D%3D 10.1016/0304-3940(92)90749-W
86. SJ Pearson A Meldrum GP Reynolds 1995 An investigation of the activities of 3-hydroxykynureninease and kynurenine aminotransferase in the brain in Huntington's disease J Neural Transm 102 67 73 1:CAS:528:DyaK28Xjt1Cmuw%3D%3D 10.1007/BF01276566
87. V Perez-De La Cruz D Elinos-Calderon Y Robledo-Arratia ON Medina-Campos J Pedraza-Chaverri SF Ali A Santamaria 2009 Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease Behav Brain Res 199 210 217 19100293 1:CAS:528:DC%2BD1MXisl2rsrk%3D 10.1016/j.bbr.2008.11.037
88. MN Perkins TW Stone 1982 An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid Brain Res 247 184 187 6215086 1:CAS:528:DyaL38Xls1Slsr4%3D 10.1016/0006-8993(82)91048-4 (Pubitemid 12028646)
89. M Pertovaara A Raitala T Lehtimaki PJ Karhunen SS Oja M Jylha A Hervonen M Hurme 2006 Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality Mech Ageing Develop 127 497 499 1:CAS:528:DC%2BD28XjvVWmsLw%3D 10.1016/j.mad.2006.01.020
90. V Politi G Deluca V Gallai O Puca M Comin 1999 Clinical experiences with the use of indole-3-pyruvic acid Adv Exp Med Biol 467 227 232 10721060 1:CAS:528:DC%2BD3cXis1ygtro%3D 10.1007/978-1-4615-4709-9-29
91. P Popoli A Pezzola ME Domenici S Sagratella G Diana MG Caporali, et al. 1994 Behavioural and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats Brain Res Bull 35 329 335 7850482 1:STN:280:DyaK2M7ltlensA%3D%3D 10.1016/0361-9230(94)90109-0 (Pubitemid 24332674)
92. GP Reynolds SJ Pearson 1989 Increased brain 3-hydroxykynurenine in Huntington's disease Lancet 2 979 980 2571888 1:STN:280:DyaK3c%2FhtlOlsA%3D%3D 10.1016/S0140-6736(89)90987-2 (Pubitemid 19255771)
93. J Rodgers TW Stone MP Barratt B Bradley PG Kennedy 2009 Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis Brain 132 1259 1267 19339256 10.1093/brain/awp074
94. S Roever AM Cesura P Hugenin R Kettler A Szente 1997 Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase J Med Chem 40 4378 4385 1:CAS:528:DyaK1cXjtFKmtg%3D%3D 10.1021/jm970467t (Pubitemid 28042317)
95. E Roze F Saudou J Caboche 2008 Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments Curr Opin Neurol 21 497 503 18607213 1:CAS:528:DC%2BD1cXpsFyjt70%3D 10.1097/WCO.0b013e328304b692
96. K Saito SP Markey MP Heyes 1992 Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse Neuroscience 51 25 39 1465184 1:CAS:528:DyaK3sXnvFaktQ%3D%3D 10.1016/0306-4522(92)90467-G
97. K Saito TS Nowak SP Markey MP Heyes 1993 Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain-regions following transient cerebral-ischemia J Neurochem 60 180 192 8417138 1:CAS:528:DyaK3sXpvFGqtQ%3D%3D 10.1111/j.1471-4159.1993.tb05836.x (Pubitemid 23006716)
98. K Saito TS Nowak K Suyama BJ Quearry M Saito JS Crowley SP Markey MP Heyes 1993 Kynurenine pathway enzymes in brain-responses to ischemic brain injury versus systemic immune activation J Neurochem 61 2061 2070 8245962 1:CAS:528:DyaK2cXivVKksA%3D%3D 10.1111/j.1471-4159.1993.tb07443.x (Pubitemid 23354062)
99. E Sapp KB Kegel N Aronin T Hashikawa Y Uchiyama K Tohyama, et al. 2001 Early and progressive accumulation of reactive microglia in the Huntington disease brain J Neuropathol Exp Neurol 60 161 172 11273004 1:STN:280: DC%2BD3M7nt1ymtQ%3D%3D (Pubitemid 32172419)
100. K Sathasivam C Hobbs L Mangiarini A Mahal M Turmaine P Doherty, et al. 1999 Transgenic models of Huntington's disease Philos Trans R Soc B Biol Sci 354 963 969 1:STN:280:DyaK1MzmtlWgug%3D%3D 10.1098/rstb.1999.0447 (Pubitemid 29477956)
101. KV Sathyasaikumar EK Stachowski L Amori P Guidetti PJ Muchowski R Schwarcz 2010 Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease J Neurochem 113 1416 1425 20236387 1:CAS:528:DC%2BC3cXnvFaktLg%3D
102. K Schroecksnadel C Murr C Winkler B Wirleitner LC Fruith D Fuchs 2004 Neopterin to monitor clinical pathologies involving interferon-gamma production Pteridines 15 75 90 1:CAS:528:DC%2BD2cXotFaqtrc%3D (Pubitemid 39280257)
103. R Schwarcz WO Jnr Whetsell RM Mangano 1983 Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain Science 219 316 318 6849138 1:CAS:528:DyaL3sXmvF2gsQ%3D%3D 10.1126/science.6849138 (Pubitemid 13222319)
104. R Schwarcz E Okuno RJ White ED Bird WO Jnr Whetsell 1988 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims Proc Natl Acad Sci USA 85 4079 4081 2967497 1:CAS:528:DyaL1cXktlKjtbc%3D 10.1073/pnas.85.11.4079
105. R Schwarcz R Pellicciari 2002 Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities J Pharmacol Exp Ther 303 1 10 12235226 1:CAS:528:DC%2BD38XnsV2ru7k%3D 10.1124/jpet.102.034439
106. R Schwarcz P Guidetti KV Sathyasaikumar PJ Muchowski 2009 Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease Progr Neurobiol 90 230 245 10.1016/j.pneurobio.2009.04.005 1:CAS:528: DC%2BC3cXisFOmu7w%3D
107. M Schwarz F Block R Topper KH Sontag J Noth 1992 Abnormalities of somatosensory evoked-potentials in the quinolinic acid model of Huntingtons-disease-evidence that basal ganglia modulate sensory cortical input Ann Neurol 32 358 364 1329611 1:STN:280:DyaK3s%2Fjslahtw%3D%3D 10.1002/ana.410320309
108. B Sperner-Unterweger C Miller B Holzner A Laich B Widner WW Fleischhacker D Fuchs 2002 Immunologic alterations in schizophrenia: neopterin, L-kynurenine, tryptophan and T-cell subsets in the acute stage of illness Pteridines 13 9 14 1:CAS:528:DC%2BD38XksFWjt78%3D (Pubitemid 34586905)
109. TW Stone 1993 The neuropharmacology of quinolinic and kynurenic acids Pharmacol Rev 45 309 379 8248282 1:CAS:528:DyaK3sXmtFKltr8%3D
110. TW Stone LG Darlington 2002 Endogenous kynurenines as targets for drug discovery and development Nat Rev Drug Discov 1 609 620 12402501 1:CAS:528:DC%2BD38XlslGqtr4%3D 10.1038/nrd870 (Pubitemid 37361524)
111. TW Stone MN Perkins 1981 Quinolinic acid: a potent endogenous excitant at amino acid receptors in the CNS Eur J Pharmacol 72 411 412 6268428 1:CAS:528:DyaL3MXlsVChs7Y%3D 10.1016/0014-2999(81)90587-2 (Pubitemid 11081065)
112. TW Stone 2001 Kynurenines in the CNS-from obscurity to therapeutic importance Prog Neurobiol 64 185 218 11240212 1:CAS:528:DC%2BD3MXhs1aqsbY%3D 10.1016/S0301-0082(00)00032-0 (Pubitemid 32195412)
113. TW Stone 2007 Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats Eur J Neurosci 25 2656 2665 17459105 10.1111/j.1460-9568.2007.05540.x (Pubitemid 46888851)
114. E Storey PB Cipolloni RJ Ferrrante NW Kowall MF Beal 1994 Movement disorder following excitotoxin lesions in primates Neuroreport 5 1259 1261 7919178 1:CAS:528:DyaK2cXmtVahu7g%3D (Pubitemid 24199811)
115. N Stoy GM Mackay CM Forrest J Christofides M Egerton TW Stone LG Darlington 2005 Tryptophan metabolism and oxidative stress in patients with Huntington's disease J Neurochem 93 611 623 15836620 1:CAS:528: DC%2BD2MXktFKgtbY%3D 10.1111/j.1471-4159.2005.03070.x (Pubitemid 40617621)
116. SJ Tabrizi J Workman PE Hart L Mangiarini A Mahal G Bates JM Cooper AHV Schapira 2000 Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Ann Neurol 47 80 86 10632104 1:STN:280:DC%2BD3c%2FpsF2ltw%3D%3D 10.1002/1531-8249(200001)47:1<80::AID- ANA13>3.0.CO;2-K (Pubitemid 30033653)
117. SB Tatter WR Galpern AT Hoogeveen O Isacson 1995 Effects of striatal excitotoxicity on Huntington-like immunoreactivity Neuroreport 6 1125 1129 7662892 1:CAS:528:DyaK2MXmslyntbc%3D 10.1097/00001756-199505300-00013
118. Tauber E, Miller-Fleming L, Mason RP, Kwan W, Clapp J, Butler NJ, Outeiro TF, Muchowski PJ, Giorgini F (2010) Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity. J Biol Chem (in press)
119. P Terness TM Bauer L Rose C Dufter A Watzlik H Simon G Opelz 2002 Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites J Exp Med 196 447 457 12186837 1:CAS:528:DC%2BD38XmsV2htLg%3D 10.1084/jem.20020052
120. AK Thakur M Jayaraman R Mishra M Thakur VM Chellgren IJ Byeon, et al. 2009 Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism Nat Struct Mol Biol 16 380 389 19270701 1:CAS:528:DC%2BD1MXivVKlsLg%3D 10.1038/nsmb.1570
121. The Huntington Study Group 1996 Unified Huntington's disease rating scale: reliability and consistency Mov Disord 11 136 142 10.1002/mds.870110204 (Pubitemid 26082779)
122. SR Thomas R Stocker 1999 Redox reactions related to indoleamine 2, 3-dioxygenase and tryptophan metabolism along the kynurenine pathway Redox Rep 4 199 220 10731095 1:CAS:528:DC%2BD3cXhtl2hu7w%3D 10.1179/135100099101534927 (Pubitemid 30088218)
123. SR Thomas PK Witting R Stocker 1996 3-Hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation J Biol Chem 271 32714 32721 8955104 1:CAS:528:DyaK2sXmvVOg 10.1074/jbc.271.51.32714 (Pubitemid 27008696)
124. MT Usdin PF Shelbourne RM Myers DV Madison 1999 Impaired synaptic plasticity in mice carrying the Huntington's disease mutation Human Mol Genet 8 839 846 1:CAS:528:DyaK1MXivFamtrw%3D 10.1093/hmg/8.5.839 (Pubitemid 29189051)
125. L Vecsei MF Beal 1991 Comparative behavioral and neurochemical studies with striatal kainic acid-lesioned or quinolinic acid-lesioned rats Pharmacol Biochem Behav 39 473 478 1719569 1:CAS:528:DyaK3MXltlegsLc%3D 10.1016/0091-3057(91)90211-J
126. ZS Vexler XN Tang MA Yenari 2006 Inflammation in adult and neonatal stroke Clin Neurosci Res 6 293 313 20300490 1:CAS:528:DC%2BD28Xht12ksb3L 10.1016/j.cnr.2006.09.008 (Pubitemid 44872641)
127. WP Weber C Feder-Mengus A Chiarugi R Rosenthal A Reschner R Schumacher P Zajaz H Misteli DM Frey D Oertli M Heberer GC Spagnoli 2006 Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8(+) T cells induced by TCR triggering or homeostatic cytokines Eur J Immunol 36 296 304 16385630 1:CAS:528:DC%2BD28XhvFWnu70%3D 10.1002/eji.200535616 (Pubitemid 43257452)
128. G Weiss A Diez-Ruiz C Murr I Theurl D Fuchs 2002 Tryptophan metabolites as scavengers of reactive oxygen and chlorine species Pteridines 13 140 144 1:CAS:528:DC%2BD3sXhtlCku7c%3D (Pubitemid 36188286)
129. ER Werner G Bitterlich D Fuchs A Hausen G Reibnegger G Szabo 1987 Human macrophages degrade tryptophan upon induction by interferon-γ Life Sci 41 273 280 3110526 1:CAS:528:DyaL2sXksFOiur4%3D 10.1016/0024-3205(87)90149-4 (Pubitemid 17109654)
130. ER Werner G Werner-Felmayer D Fuchs A Hausen G Reibnegger H Wachter 1989 Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2, 3-dioxygenase activity in human cells and cell lines by interferon-gamma Biochem J 262 861 866 2511835 1:CAS:528:DyaL1MXlvFars74%3D (Pubitemid 19225160)
131. BC White JM Sullivan DJ De Gracia BJ O'Neill RW Neumar LI Grossman JA Rafols GS Krause 2000 Brain ischemia and reperfusion: molecular mechanisms of neuronal injury J Neurol Sci 179 1 33 11054482 1:CAS:528:DC%2BD3cXnsFWqs7o%3D 10.1016/S0022-510X(00)00386-5
132. B Widner M Ledochowski D Fuchs 2000 Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences Curr Drug Metabol 1 193 204 1:CAS:528:DC%2BD3cXntlOrs7g%3D 10.2174/1389200003339063
133. H Wiendl U Feger M Mittelbronn C Jack B Schreiner C Stadelmann, et al. 2005 Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity Brain 128 2689 2704 16123145 10.1093/brain/awh609 (Pubitemid 41552952)
134. H Wiendl 2007 HLA-G in the nervous system Human Immunol 68 286 293 1:CAS:528:DC%2BD2sXjslShsrk%3D 10.1016/j.humimm.2006.10.021 (Pubitemid 46497519)
135. B Wirleitner G Neurauter K Schrocksnadel B Frick D Fuchs 2003 Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects Curr Med Chem 10 1581 1591 12871129 1:CAS:528:DC%2BD3sXls1Wru74%3D 10.2174/0929867033457179 (Pubitemid 36896559)
136. B Wirleitner V Rudzite G Neurauter C Murr U Kalnins A Erglis K Trusinskis D Fuchs 2003 Immune activation and degradation of tryptophan in coronary heart disease Eur J Clin Invest 33 550 554 12814390 1:CAS:528:DC%2BD3sXlvVSqtrs%3D 10.1046/j.1365-2362.2003.01186.x (Pubitemid 36783213)
137. H Xu GX Zhang B Ciric A Rostami 2008 IDO: a double-edged sword for T(H)1/T(H)2 regulation Immunol Lett 121 1 6 18824197 1:CAS:528: DC%2BD1cXht12lsbbK 10.1016/j.imlet.2008.08.008
138. Y Yan GX Zhang B Gran F Fallarino S Yu H Li ML Cullimore A Roatami H Xu 2010 IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis J Immunol 185 5953 5961 20944000 1:CAS:528:DC%2BC3cXhtlOhsbrI 10.4049/jimmunol.1001628
139. XQ Zhang DL Smith AB Merlin S Engemann DE Russel M Roark, et al. 2005 A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo Proc Natl Acad Sci USA 102 892 897 15642944 1:CAS:528:DC%2BD2MXis1CqtrY%3D 10.1073/pnas.0408936102 (Pubitemid 40282761)
140. BT Zhu 2010 Development of selective immune tolerance towards the allogeneic fetus during pregnancy: role of tryptophan catabolites Int J Mol Med 25 831 835 20428785 10.3892/ijmm-00000411